

# Update on Acne Vulgaris

Teresa S. Wright, MD, FAAD, FAAP

Professor

Dermatology and Pediatrics  
LeBonheur Children's Hospital  
Memphis, TN

# Disclosures

- No relevant conflicts of interest.

# Learning Objectives

- Describe the four factors of acne pathogenesis
- Assess lesion morphology and severity
- List acne medications and explain their mechanisms of action
- Design an effective treatment plan
- Counsel patients regarding acne skin care
- Review new acne medications

# Prevalence


- Extremely common!
  - 80% of adolescents and young adults 11-30 yrs<sup>1,2</sup>
  - 40-50 million in the United States <sup>3</sup>
  - costs exceed \$3 billion per year

# Psychosocial Impact

- Negative effects
  - mood, self-esteem, body image<sup>4,5</sup>
- Treatment
  - reduces anxiety and depression
  - improves quality of life<sup>6</sup>



# Pilosebaceous unit




# Acne Pathogenesis

## Four factors:

1. Sebaceous gland hyperplasia
2. Abnormal follicular desquamation
3. *Cutibacterium acnes* colonization
4. Inflammation

# Acne Pathogenesis

- Microcomedo
  - Non-inflammatory comedones
    - Blackhead (open)
    - Whitehead (closed)
  - Inflammatory lesions
    - papules, pustules, nodules, cysts



# How to Assess Patient

- Grading systems
  - Help guide therapy and assess response
  - No consensus
- Most combine lesion counting with global assessment of severity<sup>7</sup>

# Practical “System”

- **Morphology**
  - Comedonal
  - Inflammatory
  - Mixed
- **Severity**
  - Mild
  - Moderate
  - Severe
- **Sites**
  - Face, chest, back
- **Other**
  - Scarring, PIH, erythema

# Severity

**Table 1.** Classification of Acne.\*

Severity	Description
Mild	Comedones (noninflammatory lesions) are the main lesions. Papules and pustules (Fig. 1) may be present but are small and few in number (generally <10).
Moderate	Moderate numbers of papules and pustules (10–40) and comedones (10–40) are present (Fig. 2). Mild disease of the trunk may also be present.
Moderately severe	Numerous papules and pustules are present (40–100), usually with many comedones (40–100) and occasional larger, deeper nodular inflamed lesions (up to 5). Widespread affected areas usually involve the face, chest, and back (Fig. 3).
Severe	Nodulocystic acne and acne conglobata with many large, painful nodular or pustular lesions are present, along with many smaller papules, pustules, and comedones (Fig. 4A).

\* The information is from Cunliffe et al.<sup>12</sup>

### Noninflammatory lesions



Closed comedones



Open comedones

### Inflammatory lesions




Papules/pustules



Nodules

### ACNE CLASSIFICATION AND GRADING



Mild  
Papules/pustules +/++  
Nodules 0



Moderate  
Papules/pustules +++;  
Nodules +/++



Severe  
Papules/pustules +++;  
Nodules +++

# Treatment

- **TOPICAL**
  - OTC
    - Benzoyl peroxide
    - Salicylic acid
  - Prescription
    - Antimicrobials
    - Retinoids
    - Combination products
- **SYSTEMIC**
  - Antibiotics
  - OCP's
  - Isotretinoin

# OTC Topicals

- Benzoyl peroxide and Salicylic acid
- Very mild acne
- Salicylic acid less effective than benzoyl peroxide<sup>8,9</sup>

# Benzoyl Peroxide

- MOA
  - kills *C. acnes*<sup>10</sup>
  - mild comedolytic<sup>10</sup>
  - mild anti-inflammatory<sup>11, 12</sup>
- Limits development of *C. acnes* antibiotic resistance<sup>13</sup>
- Combine with retinoid to increase efficacy<sup>14</sup>
- No resistance reported<sup>15</sup>

# Benzoyl Peroxide

- “GRASE” by FDA
- Side effects
  - Irritation
  - Bleaching
  - ACD
- Variety of formulations
  - 2.5% to 10%

# Topical Antibiotics

- Clindamycin, erythromycin
- MOA
  - Antibacterial<sup>12</sup>
  - Anti-inflammatory<sup>12</sup>
- Side effects
  - Irritation
  - Colitis reported with clindamycin

# Topical Antibiotics

- Not recommended as monotherapy
  - Slow onset
  - Resistance
  - Not comedolytic
- Add topical BP or use a combo product
  - BP + clindamycin
    - Benzaclin® gel, Duac® gel
  - BP + erythromycin
    - Benzamycin® gel

# Topical Retinoids

- Mechanism of Action
  - Normalize follicular desquamation<sup>16</sup>
  - Anti-inflammatory<sup>17</sup>
  - Enhance penetration of other compounds<sup>17</sup>
- Indications
  - First line therapy for all types of acne
  - Preferred for maintenance therapy<sup>18,19</sup>
- Side Effects
  - Dryness!
  - Local irritation

# Topical Retinoids

- **Adapalene**
    - Cream 0.1%
    - \*Gel 0.1, 0.3%
    - Lotion 0.1%
  - **Tretinoi**n
    - Cream 0.025, 0.05, 0.1%
    - Gel 0.01, 0.025, 0.05%
    - Micro 0.04, 0.1 %
  - **Tazarotene**
    - Cream 0.05, 0.1%
    - Gel 0.05, 0.1%
- \*Differin™ (otc)

\* Gel 0.05% (Atralin®)  
FDA approved for ≥  
10 yrs

# Topical Retinoid Combination Products

- Tretinoiin 0.025% + Clindamycin 1.2%
  - Ziana® (FDA approved for  $\geq 12$  yrs)
  - Addition of BP recommended
  - Generic available
- Adapalene 0.1% + BP 2.5%
  - Epiduo® (FDA approved for  $\geq 9$  yrs)
  - Generic available
- Adapalene 0.3% + BP 2.5%
  - Epiduo Forte ® (FDA approved for  $\geq 12$  yrs)
  - Generic available

# Topical Retinoid Combination Products

- Pros
  - Qday
- Cons
  - Fixed retinoid (low concentration)
  - \$\$\$ (hundreds for 30-45 gm)

# Systemic Antibiotics

- Moderate to severe inflammatory acne
- Most not FDA approved for acne
  - Solodyn® (ER minocycline) at 1 mg/kg/day
    - $\geq 12$  yr
  - Seysara® (sarecycline) Oct 2018
    - $\geq 9$  yr
    - 30 d of 60 mg= approx. \$1,000
- MOA:
  - Antibacterial
  - Anti-inflammatory
- Goal is 3-4 month course
  - maintenance with topical

# Systemic Antibiotics

- Preferred oral antibiotics (for  $\geq 8$  yrs)
  - \*Doxycycline: 50-100 mg po qd-bid
  - Tetracycline: 500 mg po bid
  - Minocycline: 50-100 mg po qd-bid

# Systemic Antibiotics

- Generally well-tolerated
- Severe side effects uncommon
  - **Tetracycline:** GI upset, tooth staining (<8 yr)
  - **Doxycycline:** GI upset, photosensitivity, esophagitis
  - **Minocycline:** dyspigmentation, lupus-like reactions, pseudotumor cerebri, SJS, Drug Hypersensitivity

# Hormonal Therapy

## Combination Oral Contraceptives

- Consider for females with moderate to severe inflammatory/mixed acne
  - FDA approved for 14-15 yr
- MOA: Anti-androgen effects suppress sebum production
- Brands FDA-approved for use in acne:
  - Ortho-Tricyclen® ( $\geq 15$ )
  - Yaz® ( $\geq 14$ )
  - Estro-Step® ( $\geq 15$ )
  - Beyaz® ( $\geq 14$ )

# Hormonal Therapy

- Potential Side Effects
  - Cardiovascular Risks
    - Venous Thromboembolic Events (VTEs)
    - MI
    - Stroke
  - Cancer: Breast, Cervical
  - Osteopenia
    - Avoid in < 14 yr or within 2 yr of first menses

# New Meds

- Amzeeq® (10/2019)
  - Topical minocycline foam 4%
  - ≥ 9 yr
  - 30 gm=\$520
- Twyneo® (7/2021)
  - Encapsulated benzoyl peroxide 3% and tretinoin 0.1%
  - ≥ 9 yr
  - 30 gm=\$457

# New Meds

- Aklief® (10/2019)
  - Trifarotene cream 0.005%
  - ≥ 9 yr
  - MOA: retinoic acid receptor agonist, but unclear
  - 45 g=\$683
- Arazlo®
  - Tazarotene lotion 0.045%
  - ≥ 9 yr
  - 45 g=\$512

# New Meds

- Winlevi® (8/2020)
  - Clascoterone cream 1%
  - ≥ 12 yr
  - MOA: androgen receptor inhibitor, but unclear
  - 60 g=\$589

# Oral Retinoids

- Indications for isotretinoin
  - Severe
  - Scarring
  - Refractory
    - Including moderate cases

# Oral Retinoids (cont.)

- Mechanism of Action
  - Decreases size/activity of sebaceous glands
    - Reduces sebum production by >90%
  - Normalizes follicular keratinization
    - prevents new comedones
  - Inhibits *C. acnes*
  - Anti-inflammatory<sup>18</sup>

# Oral Retinoids (cont.)

- Common side effects
  - dry lips, skin, and eyes
  - nosebleeds
  - mild headaches
  - muscle aches
  - backaches

# Oral Retinoids (cont.)

- Potentially serious side effects
  - Teratogenic effects
    - iPledge
  - Depression, suicidal ideation
    - No causal relationship established<sup>19</sup>
  - Skeletal changes
    - Fractures, hyperostosis, epiphyseal closure<sup>20,21</sup>
  - IBD?
    - Data conflicting (UC > CD)<sup>22</sup>
    - No causal relationship established

# Other Therapies

- Complementary/Alternative
  - Limited data regarding safety and efficacy
    - Herbal compounds
    - Biofeedback
- Chemical peels
  - Glycolic and salicylic acid peels helpful for comedones

# Other Therapies

- Lasers and Light
  - Best evidence for Photodynamic Therapy (PDT)
    - Photosensitizer applied
    - Absorbed by sebaceous glands
    - Activated with light
- Intralesional Steroid Injections
  - Nodules
    - Decreased pain and swelling

# Simple Treatment Algorithm

- Mild comedonal
  - topical retinoid (or benzoyl peroxide)
- Mild inflammatory/mixed
  - topical retinoid + topical antimicrobial
- Moderate inflammatory/mixed
  - topical retinoid + topical antimicrobial + oral antimicrobial
- Severe inflammatory
  - Minimal scarring: topical retinoid + topical antimicrobial + oral antimicrobial
  - Scarring or multiple treatment failures: Isotretinoin



# Mild to moderate comedonal

- Topical retinoid





# Mild Mixed Acne

- Topical retinoid + topical antibiotic





# Moderate Mixed Acne

Topical retinoid + topical antimicrobial + oral antibiotic



# Severe Mixed/Inflammatory Acne



# Severe Mixed Acne

- Severe Mixed
  - Minimal scarring: topical retinoid + topical antimicrobial + oral antibiotic
  - More severe scarring: Isotretinoin



# Chest/Back Acne



# Chest/Back Acne

- Mild
  - Benzoyl peroxide wash
- Moderate
  - Oral antibiotic
- Severe
  - Isotretinoin

# Basic Skin Care for Acne

- Gentle cleansing 1-2 times a day
- Mild, fragrance-free cleanser
- Oil-free moisturizer with SPF 30+ bid and prn
- Avoid OTC acne washes and topicals
  - Too irritating/drying

# Address Common Acne Myths

- Acne is not caused by poor hygiene or dirt.
- Diet controversial
  - high glycemic index diet may lead to hyperinsulinemia and stimulate androgen synthesis
  - Skim milk<sup>23</sup>
  - Nutritional supplements
    - whey

Table 2 Glycemic Indices and Glycemic Loads of Common Foods		
Food	Glycemic Index	Glycemic Load*
White bread	72	10
Whole wheat bread	72	8
Baked potato	111	33
Sweet potato	61	11
Carrots	35	2
Honey	69	15
Watermelon	72	4
Banana	62	16
Grapes	59	11
Apple	39	6
Cranberry juice cocktail	68	24
Yogurt (low fat)	27	9
Skim milk	32	4
Whole milk	41	5

\* Glycemic load = glycemic index × carbohydrate content in 100 g portions. Glucose is used as the reference and has a glycemic index of 100.  
Source: References 7, 9.

# Diet and Acne

- No specific dietary changes are recommended.
- Supplements?
  - Antioxidants (e.g., zinc)
  - Probiotics
  - Fish Oil

# Other Patient Education

- Discourage picking!
  - permanent scarring
- Post-inflammatory hyperpigmentation
- Explain how to use medicines
  - Small amount
- Potential side effects
  - Expect dryness
- Consistent use for 6-8 weeks minimum

# When to Refer

- Severe Acne (cysts, nodules, scars)
- No response or poor response to treatment after 12 weeks
- If systemic antibiotics needed >1 year
- Isotretinoin being considered
  - Females will need OCP
- Acne associated with a systemic disease

- For physicians:
  - <http://www.aad.org/dermatology-a-to-z/diseases-and-treatments/a---d/acne>
  - <http://www.pedsderm.net/webinars/acne-module.html>
  - <http://www.acneandrosacea.org>
  - [https://pedsderm.net/site/assets/files/1028/1\\_spd\\_acne\\_short\\_web\\_final.pdf](https://pedsderm.net/site/assets/files/1028/1_spd_acne_short_web_final.pdf)
- For patients:
  - <http://www.aad.org/dermatology-a-to-z/for-kids>

# References

1. Kraning KK, Odland GF. Prevalence, morbidity, and cost of dermatological diseases. *J Invest Dermatol* 1979; 73 (5): 395-513.
2. Harper JC; An update on the pathogenesis and management of acne vulgaris. *J Am Acad Dermatol* 2004; 51 (1): S1-37.
3. White, Gary. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. *J Am Acad Dermatol* 1998; 39: S34-7.
4. Lasek RJ, Chren M-M. Acne vulgaris and the quality of life of adult dermatology patients. *Arch Dermatol* 1998; 134: 454-8.
5. Aktan S et al. Anxiety, depression, and nature of acne vulgaris in adolescents. *Int J Dermatol*. 2000;39(5): 354- 357.
6. Rubinow DR, Peck GL, Squillace KM et al. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. *J Am Acad Dermatol* 1987; 17: 25-32.
7. Strauss JS et al. Guidelines of care for acne vulgaris management. *J Am Acad Dermatol*; 56(4):651-63.
8. Shalita AR. Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. *Cutis*. 1981; 28(5): 556-558, 561.
9. Shalita AR. Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. *Clin Ther*. 1989; 11 (2): 264-267.
10. Kligman et al. New uses for benzoyl peroxide: a broad spectrum antimicrobial agent. *Int J Dermatol*. 1977; 16(5): 413-417.

# References

11. Hegemann L et al. Anti-inflammatory actions of benzoyl peroxide effects on the generation of reactive oxygen species by leucocytes and the activity of protein kinase C and calmodulin. *Br J Dermatol.* 1994; 130(5): 569-575.
12. Krakowski AC et al. Practical considerations in acne treatment and the clinical impact of topical combination therapy. *Pediatr Dermatol* 2008; 25 (suppl 1): 1-14.
13. Shalita AR et al. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. *Cutis.* 2003; 72(2): 167-172.
14. Pariser DM et al. Long-term safety and efficacy of a unique fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. *J Drugs Dermatol.* 2007; 6(9): 899-905.
15. Leyden JJ et al. Antibiotic resistant *Propionibacterium acnes* suppressed by a benzoyl peroxide cleanser 6%. *Cutis.* 2008; 82(6): 417-421.
16. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. *J Am Acad Dermatol.* 2003;49 (suppl 3): S200-S210.
17. Thiboutot D. et al. Global Alliance to improve outcomes in acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. *J Am Acad Dermatol.* 2009; 60 (suppl 5): S1-S50.
18. Gollnick H et al. global Alliance to Improve outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. *J Am Acad Dermatol.* 2003;49(suppl 1): S1-S37.
19. Cohen J et al. No association found between patients receiving isotretinoin for acne and the development of depression in a Canadian prospective cohort. *Can J Clin Pharmacol.* 2007; 14(2): e227-e233.

# References

20. Vestergaard P, et al. High-dose treatment with Vitamin A analogues and risk of fractures. *Arch Dermatol* 2010;146(5): 478-482. References
21. Steele RG, et al. Premature epiphyseal closure secondary to single course vitamin A therapy. *Aust NZ J Surg.* 1999; 69(11):825-827.
22. Guslandi M. Isotretinoin and inflammatory bowel disease. *Am J Gastroenterol.* 2006; 101(7): 1569-1573.
23. Melnik BC, et al. Potential role of FOX 01 and mTORC1 in the pathogenesis of Western diet-induced acne. *Experimental Dermatology.* 2013; 22, 311-315.
24. Eichenfield LF, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. *Pediatrics.* 2013; 131(suppl 3): S163-S186.